← board
AVXL
Anavex Life Sciences Corp.distress 1/10 · well-funded / low risk$2.550%today-81% from 52w high
Psychiatry / CNS 1
Lead: Early Alzheimer's Disease · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$132M
Runway
3.4 yrs
Shares 1y
+8%
Price & events
-51.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+9.0%
1W
-1.2%
1M
-23.0%
3M
-51.5%
6M
-81.0%
1Y
-61.2%
2Y
-87.8%
5Y
-51.8%
All
Overview
- Market Cap
- $236.31M
- Volume
- 54.85K
- 52 Week Range
- $2.34 – $13.41
- Total Shares
- 92.67M
- Float Shares
- 89.78M
- Short %
- 15.98%
- % Held by Insiders
- 3.12%
- % Held by Institutions
- 43.85%
- RVOL
- 0.04x
- Beta
- 1.14
Pipeline stages · 1 programs
ANAVEX3-71 oral capsules
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-06-30 | Phase 2 | ANAVEX3-71 oral capsules | Schizophrenia | 71 | active not recruiting |
Catalyst news & presentations · 5
- AD/PD 2026 ConferenceGuided 40%conferencedata presentationsecondaryBlarcamesine · Presentation of new AD-004 Phase IIb/III trial data.PR wire
- 2026-07-23Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-03-25withdrawalblarcamesine · Withdrawn EU marketing authorization application for early Alzheimer's disease following CHMP feedback.SEC 8-K
- December 2025chmp opinionCHMP (EU)blarcamesine · CHMP expected to adopt formal opinion on MAA for blarcamesine.SEC 8-K
- 2025-11-14withdrawalblarcamesine · CHMP negative trend vote on MAA for early Alzheimer's disease; company to request re-examination.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-31D. Boral CapitalBuy
- 2026-03-26D. Boral CapitalBuy
- 2026-03-23D. Boral CapitalBuy
- 2026-02-10HC Wainwright & Co.Buy
- 2026-02-09D. Boral CapitalBuy
- 2026-01-06D. Boral CapitalBuy
Competitors — Early Alzheimer's Disease
Recent news
- 2026-07-20Anavex Life Sciences Submits Plan to Regain Compliance With Nasdaq Timely Filing Rule - marketscreener.com
- 2026-07-20Anavex Life Sciences submits compliance plan to Nasdaq after 10-Q delay - TradingView
- 2026-07-14Anavex Life Sciences Corp (AVXL) Institutional Confidence - TradingKey
- 2026-07-13Anavex Life Sciences Corp (AVXL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-07-01How Anavex Life Sciences Corp. (AVXL) Affects Rotational Strategy Timing - Stock Traders Daily
- 2026-07-01How Anavex Life Sciences Corp. (AVXL) Affects Rotational Strategy Timing - Stock Traders Daily
- 2026-06-30Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewir - The National Law Review
- 2026-06-29Anavex Life Sciences Corp.(NasdaqGS: AVXL) added to Russell 2000 Value Benchmark - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.